Related references
Note: Only part of the references are listed.Chimeric antigen receptor T-cell therapy in adults with B-cell acute lymphoblastic leukemia
Punita Grover et al.
BLOOD ADVANCES (2022)
Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods
Michaela Kotrova et al.
BLOOD ADVANCES (2022)
DUX4r, ZNF384r and PAX5-P80R mutated B-cell precursor acute lymphoblastic leukemia frequently undergo monocytic switch
Michaela Novakova et al.
HAEMATOLOGICA (2021)
Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial
Rathana KIM et al.
BLOOD (2021)
How I investigate minimal residual disease in acute lymphoblastic leukemia
Rodolfo P. Correia et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2021)
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia
Josep-Maria Ribera et al.
BLOOD (2021)
Relative expansion of CD19-negative very-early normal B-cell precursors in children with acute lymphoblastic leukaemia after CD19 targeting by blinatumomab and CAR-T cell therapy: implications for flow cytometric detection of minimal residual disease
Ekaterina Mikhailova et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR
Matthew J. Wieduwilt et al.
LEUKEMIA (2021)
Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia
Michela Ansuinelli et al.
HEMATOLOGICAL ONCOLOGY (2021)
Acute Lymphoblastic Leukemia, Version 2.2021
Patrick A. Brown et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia
Lori Muffly et al.
BLOOD ADVANCES (2021)
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial
Elias Jabbour et al.
LEUKEMIA RESEARCH (2020)
Impact of detectable measurable residual disease on umbilical cord blood transplantation
Frederic Baron et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement
Jack Bartram et al.
SEMINARS IN HEMATOLOGY (2020)
Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes
Nicholas J. Short et al.
BLOOD (2020)
A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia
Renato Bassan et al.
HAEMATOLOGICA (2019)
ClonoSEQ assay for the detection of lymphoid malignancies
Anna Monter et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2019)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Wendy Stock et al.
BLOOD (2019)
Minimal Residual Disease-Based Long-Term Efficacy of Reduced-Intensity Conditioning Versus Myeloablative Conditioning for Adult Philadelphia-Positive Acute Lymphoblastic Leukemia
Jae-Ho Yoon et al.
CANCER (2019)
More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling
Peter Bader et al.
BLOOD ADVANCES (2019)
High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments
Jack Bartram et al.
HAEMATOLOGICA (2018)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response
Caner Saygin et al.
LEUKEMIA & LYMPHOMA (2018)
High throughput sequencing in acute lymphoblastic leukemia reveals clonal architecture of central nervous system and bone marrow compartments
Jack Bartram et al.
HAEMATOLOGICA (2018)
Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies
Giovanni Cazzaniga et al.
HAEMATOLOGICA (2018)
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
Nicola Goekbuget et al.
BLOOD (2018)
Droplet Digital PCR Is a Robust Tool for Monitoring Minimal Residual Disease in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia
Nicoletta Coccaro et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
Elias Jabbour et al.
LANCET HAEMATOLOGY (2018)
Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia
Prisca Theunissen et al.
BLOOD (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Blinatumomab-induced lineage switch of B-ALL with t(4:11) (q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis
C. L. Haddox et al.
BLOOD CANCER JOURNAL (2017)
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia AMeta-analysis
Donald A. Berry et al.
JAMA ONCOLOGY (2017)
How do we measure MRD in ALL and how should measurements affect decisions. Re: Treatment and prognosis?
Xueyan Chen et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis
Aaron C. Shaver et al.
CLINICS IN LABORATORY MEDICINE (2017)
Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology
Lenka Hovorkova et al.
BLOOD (2017)
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients
Olga Sala Torra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003
Jack Bartram et al.
ARCHIVES OF DISEASE IN CHILDHOOD (2016)
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Nicholas J. Short et al.
BLOOD (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Accurate Sample Assignment in a Multiplexed, Ultrasensitive, High-Throughput Sequencing Assay for Minimal Residual Disease
Jack Bartram et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Minimal Residual Disease Detection and Evolved IGH Clones Analysis in Acute B Lymphoblastic Leukemia Using IGH Deep Sequencing
Jinghua Wu et al.
FRONTIERS IN IMMUNOLOGY (2016)
Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies
Jacques J. M. van Dongen et al.
BLOOD (2015)
Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia
Nathalie Dhedin et al.
BLOOD (2015)
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier et al.
BLOOD (2015)
Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival
Aaron C. Logan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Drug Resistance and BCR-ABL Kinase Domain Mutations in Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia From the Imatinib to the Second- Generation Tyrosine Kinase Inhibitor Era
Simona Soverini et al.
CANCER (2014)
Treatment of High-Risk Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial
Josep-Maria Ribera et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage
L. Slamova et al.
LEUKEMIA (2014)
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia Results of cancer and leukemia group B study 19802
Wendy Stock et al.
CANCER (2013)
Technical issues: flow cytometry and rare event analysis
B. D. Hedley et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2013)
Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial
Ajay Vora et al.
LANCET ONCOLOGY (2013)
A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
Ching-Hon Pui et al.
SEMINARS IN HEMATOLOGY (2013)
Overview of clinical flow cytometry data analysis: recent advances and future challenges
Carlos E. Pedreira et al.
TRENDS IN BIOTECHNOLOGY (2013)
Lineage switch in childhood acute leukemia: An unusual event with poor outcome
Jorge G. Rossi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Has MRD monitoring superseded other prognostic factors in adult ALL?
Monika Brueggemann et al.
BLOOD (2012)
Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies
Nicola Goekbuget et al.
BLOOD (2012)
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
Malek Faham et al.
BLOOD (2012)
Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial
Jonathan I. Sive et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes
J. J. M. van Dongen et al.
LEUKEMIA (2012)
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz et al.
BLOOD (2008)
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia.: The Polish Adult Leukemia Group ALL 4-2002 MRD Study
Jerzy Holowiecki et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia
Orietta Spinelli et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment:: data from the GMALL 06/99 and 07/03 trials
Thorsten Raff et al.
BLOOD (2007)
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data
V. H. J. van der Velden et al.
LEUKEMIA (2007)
Impact of two independent bone marrow samples on minimal residual disease monitoring in childhood acute lymphoblastic leukaemia
VHJ van der Velden et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia
M Brüggemann et al.
BLOOD (2006)
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
H Kantarjian et al.
CANCER (2004)
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia
E Coustan-Smith et al.
BLOOD (2002)
Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL
VHJ van der Velden et al.
LEUKEMIA (2002)
Share Paper
